<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6699">
  <stage>Registered</stage>
  <submitdate>20/01/2017</submitdate>
  <approvaldate>20/01/2017</approvaldate>
  <nctid>NCT03052608</nctid>
  <trial_identification>
    <studytitle>A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC</studytitle>
    <scientifictitle>A Phase 3, Randomized, Open-label Study Of Lorlatinib (Pf-06463922) Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of Patients With Advanced Alk-positive Non-small Cell Lung Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-003315-35</secondaryid>
    <secondaryid>B7461006</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Carcinoma, Non-Small-Cell Lung</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Lorlatinib
Treatment: drugs - Crizotinib

Experimental: Lorlatinib - Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously

Active Comparator: Crizotinib - Crizotinib single agent, 250 mg (1 x 250) oral capsules, BID, continuously


Treatment: drugs: Lorlatinib
ALK-positive NSCL treatment

Treatment: drugs: Crizotinib
ALK-positive NSCL treatment

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival (PFS) based on blinded independent central review (BICR) assessment - PFS is defined as the time from randomization to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first.</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival (OS) - OS is defined as time from date of randomization to date of death due to any cause</outcome>
      <timepoint>From time of Study Start up to 125 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PFS based on Investigator's assessment - PFS is defined as the time from randomization to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first.</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response (OR) based on BICR and on Investigator's assessments - OR defined as complete response (CR) or partial response (PR) per RECIST version 1.1 recorded from randomization until disease progression or start of new anti-cancer therapy</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Intracranial Objective Response (IC-OR) based on BICR assessment - IC-OR defined as complete response (CR) or partial response (PR) based on intracranial disease in the subset of patients with at least 1 intracranial lesion per RECIST version 1.1 (modified) recorded from randomization until disease progression or start of new anti-cancer therapy</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Intracranial Time to Progression (IC-TTP) based on BIRC assessment - IC-TTP defined as the time from randomization to the date of the first documentation of objective progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of Response (DR) based on BIRC assessment - DR defined, for patients with an OR per RECIST version 1.1, as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Tumor Response (TTR) based on BIRC assessment - TTR defined, for patients with a confirmed OR, as the time from the date of randomization to the first documentation of objective response (CR or PR) which is subsequently confirmed</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Benefit Response (CBR) based on BIRC assessment - CBR defined as Best Overall Response of confirmed CR or PR at any time, or SD lasting at least 24 weeks from randomization</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PFS2 based on investigator's assessment - PFS2 is defined as the time from randomization to the date of progression of disease on first subsequent systemic anti-cancer therapy, or death from any cause, whichever occurs first</outcome>
      <timepoint>From time of Study Start up to 45 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse Event (AE) as graded by NCI CTCAE v 4.03) - Frequency of patients experiencing treatment-emergent AEs (TEAEs)</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Laboratory abnormalities as graded by NCI CTCAE v 4.03) - Frequency of patients with laboratory test abnormalities</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Vital signs (blood pressure, pulse rate) and body weight - Summary of actual values and changes from baseline</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Electrocardiograms (ECG) - Summary of actual values and changes from baseline</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Echocardiograms or multigated acquisition scan (MUGA) - Summary of actual values and changes from baseline</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ophthalmology - Summary of changes from screning results</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PRO as assessed by EORTC QLQ-C30, EORTC QLQ LC13, and EQ-5D-5L - Summary of absolute scores and mean change of absolute scores from baseline</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor tissue biomarkers - Summary of baseline levels and changes from baseline</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Peripheral blood cfDNA (circulating free Deoxyribonucleic acid) biomarkers - Summary of baseline levels and changes from baseline</outcome>
      <timepoint>From time of Study Start up to 33 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically or cytologically confirmed diagnosis of locally advanced or metastatic
             ALK-positive NSCLC; at least 1 extracranial measurable target lesion not previously
             irradiated. CNS metastases allowed if asymptomatic and not currently requiring
             corticosteroid treatment.

          -  Availability of an archival FFPE tissue specimen.

          -  No prior systemic NSCLC treatment.

          -  ECOG PS 0, 1, or 2.

          -  Age =18 years .

          -  Adequate Bone Marrow, Liver, Renal, Pancreatic Function

          -  Negative pregnancy test for females of childbearing potential</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Spinal cord compression unless good pain control attained

          -  Major surgery within 4 weeks prior to randomization.

          -  Radiation therapy within 2 weeks prior to randomization, including stereotactic or
             partial brain irradiation. Whole brain irradiation within 4 weeks prior to
             randomization

          -  Active bacterial, fungal, or viral infection

          -  Clinically significant cardiovascular disease, active or within 3 months prior to
             enrollment. Ongoing cardiac dysrhythmias, uncontrolled atrial fibrillation,
             bradycardia or congenital long QT syndrome

          -  Predisposing characteristics for acute pancreatitis in the last month prior to
             randomization.

          -  History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial
             fibrosis or interstitial lung disease

          -  Active malignancy (other than NSCLC, non melanoma skin cancer, in situ cervical
             cancer, papillary thyroid cancer, LCIS/DCIS of the breast, or localized prostate
             cancer) within the last 3 years prior to randomization.

          -  Concurrent use of any of the following food or drugs within 12 days prior to the first
             dose of lorlatinib or crizotinib.

               1. known strong CYP3A inhibitors .

               2. known strong CYP3A inducers

               3. known P gp substrates with a narrow therapeutic index

          -  Concurrent use of CYP3A substrates with narrow therapeutic indices within 12 days
             prior to the first dose of lorlatinib or crizotinib.

          -  Other severe acute or chronic medical or psychiatric condition, including recent or
             active suicidal ideation or behavior, or laboratory abnormality that may increase the
             risk associated with study participation or interfere with the interpretation of study
             results

          -  Investigational site staff members directly involved in the conduct of the study and
             their family members, or Pfizer employees, including their family members, directly
             involved in the conduct of the study.

          -  Participation in other studies involving investigational drug(s) within 2 weeks prior
             to study entry and/or during study participation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional(has expanded access)</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>14/04/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>280</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>23/10/2023</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <postcode>3000 - Melbourne</postcode>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Charleroi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aalborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Herlev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Mans</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-Priest en Jarez cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint-Priest en Jarez</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Suresnes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse cedex 9</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Deutschland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Berka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gauting</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Loewenstein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>PG</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ehime</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hokkaido</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hyogo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ishikawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Miyagi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shizuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Yamaguchi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Koto-ku, Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Niigata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Okayama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokushima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Wakayama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Ulsan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Harderwijk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kursk Region</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Omsk Region</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Arkhangelsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Chelyabinsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kursk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Merseyside</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Suffolk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Midlands</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to
      crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC
      patients who are treatment na√Øve and to compare lorlatinib to crizotinib with respect to
      overall survival in the same population</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03052608</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address />
      <phone>1-800-718-1021</phone>
      <fax />
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>